Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Corgenix Cancels Genesis Bioventures Merger

By Labmedica staff writers
Posted on 08 Feb 2005
Due to a lack of progress toward the completion of the financing and the expiration dates on legal documents, Corgenix Medical Corp (Denver, CO, USA) has terminated its proposed U.S.$6 million merger with Genesis Bioventures (Surrey, Canada).

Corgenix develops and manufactures anti-phospholipid test kits, and its anticardiolipin (aCL) assay has been cleared by the U.S. More...
Food and Drug Administration (FDA). The company is focused on the development of specialized diagnostic kits for immunology disorders, vascular diseases, and bone and joint disorders.

"We regret that it was necessary to terminate the proposed merger after spending so much time and energy on it,” stated Douglass Simpson, president of Corgenix. "However, on the positive side, Corgenix is investigating a broad range of business opportunities, including the pursuit of our own equity financing.”





Related Links:
Corgenix
Genesis Bioventures

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Thyroid Test
Anti-Thyroid EIA Test
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.